12 stories from 4 sources
Supporting Articles
The Ebola outbreak in Congo has killed more than 4,000 people, while an Ebola treatment center was burned down amid efforts to contain the spread. The attack further disrupts care in an outbreak already described as the fastest-growing in history.
10:25 AMStat News
Western biopharma companies are increasingly licensing or acquiring drug candidates from Chinese developers as major products approach patent expiration. The shift reflects China’s growing role as a source of pharmaceutical innovation, not just manufacturing.
8:31 AMCNBCNovartis will license an mRNA-based autoimmune therapy from China’s Abogen Biosciences in a deal valued at up to $7.8 billion.
2:47 AMBloomberg MarketsEli Lilly and Novo Nordisk are developing amylin-based medicines as a new biological approach to treating obesity and diabetes. The drugs could complement or extend the effects of GLP-1 therapies.
1:55 PMCNBCSummary
The Ebola outbreak in Congo has killed more than 4,000 people, while an Ebola treatment center was burned down amid efforts to contain the spread. The attack further disrupts care in an outbreak already described as the fastest-growing in history.
The destruction of a treatment center turns insecurity and public distrust into direct threats to
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Epidemic control depends on public access and trust, both of which collapse when treatment sites become targets.
2 stories · 2 sources
Summary
Western biopharma companies are increasingly licensing or acquiring drug candidates from Chinese developers as major products approach patent expiration. The shift reflects China’s growing role as a source of pharmaceutical innovation, not just manufacturing.
The patent cliff is pushing large drugmakers to buy external pipelines faster, and Chinese biotech
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The next wave of blockbuster drugs may depend more heavily on cross-border deals with Chinese biotech companies.
Summary
Novartis will license an mRNA-based autoimmune therapy from China’s Abogen Biosciences in a deal valued at up to $7.8 billion.
The agreement gives Novartis access to a Chinese-developed mRNA platform while giving Abogen capital and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The deal could accelerate mRNA treatments for autoimmune conditions and deepen reliance on cross-border Chinese biotech partnerships.
Summary
Eli Lilly and Novo Nordisk are developing amylin-based medicines as a new biological approach to treating obesity and diabetes. The drugs could complement or extend the effects of GLP-1 therapies.
The next competitive frontier in obesity treatment is shifting beyond GLP-1s toward drugs that activate
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Amylin could reshape the obesity-drug market by giving patients alternatives to increasingly crowded GLP-1 treatments.
A curated list of other prominent stories from this day.
Experts expect many consumers to face health insurance premium increases of about 10% or more in 2027. Rising medical expenses and broader pressure on insurers are driving the projections.
12:26 PMCNBC
More young people with opioid use disorder are receiving addiction medications, but only a small share starts treatment and few remain on it for long. A new study identifies retention as the central weakness in care.
11:00 AMStat News
Eli Lilly is launching LillyDirect in Australia to deliver Mounjaro directly to patients' homes. Australian doctors and pharmacists have criticized the model for bypassing traditional pharmacy channels.
9:58 AMStat News
Pennsylvania’s fifth reported measles death has renewed questions about the scale of the state’s outbreak and its connection to wider transmission across the country. The full size of the outbreak remains difficult to establish from the available reporting.
7:53 AMStat News
The NIH awarded its available grant funding for fiscal 2026, but researchers faced delays and limited visibility into how decisions were made. Grants involving health disparities, race, and ethnicity continued to decline, while other administration priorities showed little progress.
4:30 AMStat News
A pharmacist argues that federal law and the 340B drug discount program have not kept pace with orphan-designated medicines that serve multiple uses. The result is uncertainty over how discounts should apply when a drug’s indications extend beyond its original rare-disease designation.
4:30 AMStat News
A physician who treated heat stroke at the New York City Marathon calls for evidence-based medical plans for extreme heat. The argument is that race organizers must adapt preparation and emergency response to worsening heat risks.
4:30 AMStat NewsSummary
Experts expect many consumers to face health insurance premium increases of about 10% or more in 2027. Rising medical expenses and broader pressure on insurers are driving the projections.
A double-digit increase would push more of the healthcare cost burden onto households and employers.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Higher premiums could make coverage less affordable and accelerate tradeoffs over benefits, networks, and out-of-pocket costs.
Summary
More young people with opioid use disorder are receiving addiction medications, but only a small share starts treatment and few remain on it for long. A new study identifies retention as the central weakness in care.
The problem has shifted from access alone to continuity: prescribing has improved without producing durable
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Short treatment duration limits the protective effect of medications during a period when young people face high overdose risk.
Summary
Eli Lilly is launching LillyDirect in Australia to deliver Mounjaro directly to patients' homes. Australian doctors and pharmacists have criticized the model for bypassing traditional pharmacy channels.
Lilly's move shifts more of the prescribing and dispensing journey toward the manufacturer, giving it
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Direct-to-consumer drug delivery could reshape how high-demand medicines reach patients and challenge the existing pharmacy system.
Summary
Pennsylvania’s fifth reported measles death has renewed questions about the scale of the state’s outbreak and its connection to wider transmission across the country. The full size of the outbreak remains difficult to establish from the available reporting.
The fifth death confirms that the outbreak is producing severe consequences, while uncertainty about case
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The outbreak shows how declining or uneven measles vaccination coverage can turn a preventable disease into a persistent public-health threat.
Summary
The NIH awarded its available grant funding for fiscal 2026, but researchers faced delays and limited visibility into how decisions were made. Grants involving health disparities, race, and ethnicity continued to decline, while other administration priorities showed little progress.
The central shift is not a funding shortfall but an increasingly unpredictable allocation process. Researchers
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Unclear funding priorities can reshape the research pipeline before Congress or the public sees a formal budget cut.
Summary
A pharmacist argues that federal law and the 340B drug discount program have not kept pace with orphan-designated medicines that serve multiple uses. The result is uncertainty over how discounts should apply when a drug’s indications extend beyond its original rare-disease designation.
The legal problem is that a designation built around one rare condition can govern a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Clearer rules would determine whether 340B savings follow the drug’s designation or the specific use for which it is prescribed.
Summary
A physician who treated heat stroke at the New York City Marathon calls for evidence-based medical plans for extreme heat. The argument is that race organizers must adapt preparation and emergency response to worsening heat risks.
Extreme heat is turning marathon medicine from a contingency issue into a core planning requirement.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Climate-driven heat raises the risk of preventable illness and makes medical preparedness central to whether mass races can be safely held.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!
